8 research outputs found

    Validação para a população portuguesa do instrumento C3 e da escala PPOS e caracterização do currículo oculto da FCS-UBI em relação ao cuidado centrado no paciente

    Get PDF
    Introdução: O cuidado centrado no paciente tem vindo a ser proposto como um mĂ©todo clĂ­nico com contribuição fundamental para a qualidade dos serviços de saĂșde. Assim, ao longo do tempo, tem-se vindo a constatar a importĂąncia de transmitir aos estudantes de medicina conceitos relacionados com este tipo de cuidado no seu relacionamento com os doentes. No entanto, vĂĄrios estudos demonstram um declĂ­nio nos comportamentos e atitudes centradas no paciente em estudantes de medicina ao longo do seu percurso acadĂ©mico. Por trĂĄs destes achados poderĂĄ estar a influĂȘncia negativa do currĂ­culo oculto. Conhecer e reflectir sobre o currĂ­culo oculto de uma escola mĂ©dica Ă© o primeiro passo no caminho para o modificar e/ou minimizar os seus potenciais efeitos negativos na formação mĂ©dica. Assim, em 2005, foi desenvolvido e validado em lĂ­ngua inglesa o Instrumento C3, um questionĂĄrio que pretende caracterizar o currĂ­culo oculto de uma escola mĂ©dica no que diz respeito ao cuidado centrado no paciente; sempre que se aplicou este questionĂĄrio, foram tambĂ©m avaliadas as atitudes dos estudantes face Ă  relação mĂ©dico-paciente, atravĂ©s da escala PPOS. Objectivos: validar e adaptar para a população portuguesa o Instrumento C3 e a escala PPOS; caracterizar o CurrĂ­culo Oculto da FCS-UBI no domĂ­nio dos cuidados centrados no paciente. Material e mĂ©todos: apĂłs autorização dos autores de ambos os questionĂĄrios para os validar e aplicar, foi efectuado um rigoroso processo de tradução, retroversĂŁo e prĂ©-teste das duas escalas em estudo. Os questionĂĄrios foram aplicados aos alunos do 5Âș e 6Âș ano do MIM da FCS-UBI. Foram tambĂ©m recolhidos alguns dados demogrĂĄficos, com intuito de melhor caracterizar a população estudada. As respostas foram analisadas estatisticamente, aplicando conceitos de anĂĄlise de validade e fiabilidade (AFE e coeficiente alfa de Cronbach), descritiva e inferencial (MANCOVA). Resultados: O instrumento C3 e a escala PPOS foram aplicados a 145 alunos, conseguindo-se uma taxa de resposta de 94%. O Instrumento C3 em lĂ­ngua portuguesa apresentou uma boa consistĂȘncia interna em todas as dimensĂ”es estudadas. O mesmo nĂŁo se verificou no caso da escala PPOS, tendo sido identificados problemas ao nĂ­vel da validade, com a AFE a identificar 6 dimensĂ”es na escala; e ao nĂ­vel da fiabilidade, com estas dimensĂ”es, bem como as descritas pelos autores da versĂŁo original, a apresentarem baixas consistĂȘncias internas. ConclusĂŁo: Relativamente Ă  escala PPOS, recomenda-se que apenas se considerem os resultados obtidos na totalidade da escala e nĂŁo aqueles obtidos nas duas dimensĂ”es originalmente descritas ou nas descritas neste estudo. A versĂŁo em LĂ­ngua Portuguesa do Instrumento C3 provou ser um ferramenta vĂĄlida e fiĂĄvel para caracterizar o currĂ­culo oculto de uma escola mĂ©dica no domĂ­nio do cuidado centrado no paciente. Na FCS-UBI, o currĂ­culo oculto parece ser comparĂĄvel ao de outros paĂ­ses nas trĂȘs ĂĄreas avaliadas pelo Instrumento C3, apesar de uma anĂĄlise mais detalhada evidenciar alguns pontos em que a instituição de ensino deverĂĄ desenvolver estratĂ©gias que procurem modificĂĄ-lo ou minimizar os seus efeitos negativos sobre o desenvolvimento humano e profissional dos seus estudantes.Introduction: Patient-centred care has been proposed as a fundamental clinical method contributing towards the quality of healthcare. In this context, the importance of conveying concepts related to this type of care to medical students in their relationship with patients has been acknowledged. However, several studies have shown a decline in patient-centred behaviours and attitudes in medical students, throughout their academic pathway. The negative influence of a hidden curriculum may underlie these results. To get to know and reflect upon the hidden curriculum of a medical school is the first step in the path towards modifying it and/or minimizing its potential negative effects upon medical training. Thus, in 2005, the C3 tool was developed and validated in the English language. C3 is a questionnaire which aims to characterize the hidden curriculum of a medical school as far as patientcentred care is concerned. Whenever this questionnaire was applied, student attitudes in terms of doctor-patient relationship were also analysed using the PPOS scale. Objectives: to validate and adapt the C3 tool and the PPOS scale to the portuguese population and to characterize the hidden curriculum in FCS-UBI in what concerns patientcentred care. Material and methods: Upon obtaining authorisation from the authors of both questionnaires to validate and apply them, a rigorous process of translation, back-translation and pre-testing of both scales under study was carried out. Questionnaires were applied to year 5 and year 6 students of the FCS-UBI medical course. Some demographic data was also taken, in order to better characterize the population under study. Responses were analysed statistically, by applying concepts of validity and reliability tests (AFE and CronbachÂŽs alpha coefficient), as well as descriptive and inferential tests (MANCOVA). Results: The C3 Instrument and PPOS were completed for 145 students, with a response rate of 94%. C3 Instrument revealed a good internal consistency in all the studied dimensions. The same was not true for PPOS – we found validity issues, with the factorial exploratory analysis identifying 6 dimensions in the scale; the majority of these dimensions as well as the two previously described by the authors of the scale presented poor internal consistencies. Conclusion: we believe that the PPOS’s original dimensions and the ones found in this study should not be used to evaluate Portuguese medical students’ attitudes towards patientcentred care. The Portuguese version of C3 Instrument proved to be a valid and reliable tool to characterize the patient-centredness of hidden curricula in medical schools. The results at FCS-UBI seem to be comparable to the ones found in USA medical schools; after a more detailed analysis, we found some points where some intervention is needed to modify it or to decrease its negative impact upon human and professional development of medical students

    Reasons for Declining Venom Immunotherapy

    Get PDF
    Introduction: Hymenoptera venom allergy is associated with significant morbidity and deterioration in health-related quality of life, and risk of fatal systemic reactions. Although venom immunotherapy is safe and the only effective treatment in allergic individuals, some patients prefer not to pursue this treatment. Since 2011, when the 50% reimbursement was stopped, patients must fully support the cost of immunotherapy. This study aimed to ascertain the reasons why patients decline immunotherapy. Material and Methods: A medical records review of all patients proposed to receive venom immunotherapy at an Allergy and Clinical Immunology Department in Porto, Portugal, between 2006 and 2015, followed by a phone interview to patients refusing treatment. Results: A total of 83 subjects were enrolled, with a mean (± SD) age of 44.4 (14.7) years and 55 (66%) males; 27 refused venom immunotherapy between 2006 and 2015. Nineteen were interviewed and 14 of those stated price as the main reason for declining treatment. The only identified risk factor associated with immunotherapy refusal was being proposed after 2011 (OR: 3.29; 95% CI: 1.12 – 9.68; p = 0.03). Discussion: The number of patients refusing venom immunotherapy doubled since reimbursement was withdrawn. Price was identified as the major obstacle to treatment completion. Immunotherapy proposal after reimbursement was stopped was associated with a 3-fold increase in the risk of refusing treatment. Conclusion: These findings show how economic decisions may have a detrimental effect on patient care, as immunotherapy refusal left them exposed to an avoidable life-threatening risk

    Paraglomus pernambucanum sp. nov. and Paraglomus bolivianum comb. nov., and biogeographic distribution of Paraglomus and Pacispora

    Get PDF
    Paraglomus pernambucanum sp. nov. (Paraglomeromycetes) was found in a tropical dry forest in the semi-arid Caatinga biome of Pernambuco State (NE Brazil), in a cowpea and in two maize production sites. It was characterized by combined morphological and molecular analyses on the spores isolated from field soil samples. Another species, Pacispora boliviana (Glomeromycetes), first described only by spore morphology, had been known from another semi-arid biome in Southern America, the Gran Chaco in Bolivia. We detected this fungus now also at different locations in semi-arid to semi-humid NE Brazil. As for P. pernambucanum phylogenetic analyses were performed on nuclear ribosomal RNA gene sequences of the LSU region. For P. boliviana, the spores for these analyses originated from a trap culture inoculated with soils from the type location. The results now revealed that also P. boliviana belongs to Paraglomus. It grouped in a separate monophyletic cluster adjacent to P. pernambucanum, to P. brasilianum, P. laccatum and the type species P. occultum. Thus, P. boliviana is transferred to Paraglomus, as Paraglomus bolivianum comb. nov. Remarkably, it is the first species known in the Paraglomeromycetes with pigmented spores. Paraglomus pernambucanum and P. bolivianum have several features in common: e.g. bi-walled spores, and densely pitted surface ornamentations on the structural layer of the outer wall. Spores of the two species can be distinguished by color and the diagnostic nature of their pitted ornamentation. The current knowledge about the global distribution of Paraglomus and Pacispora species is summarized and discussed

    Abstracts from the Food Allergy and Anaphylaxis Meeting 2016

    Get PDF

    7th drug hypersensitivity meeting: part one

    No full text
    Table of contents Oral Abstracts O1 Functionally distinct HMGB1 isoforms correlate with physiological processes in drug-induced SJS/TEN Daniel F. Carr, Wen-Hung Chung, Rosalind E. Jenkiins, Mas Chaponda, Gospel Nwikue, Elena M. Cornejo Castro, Daniel J. Antoine, Munir Pirmohamed O2 Hypersensitivity reactions to beta-lactams, does the t cell recognition pattern influence the clinical picture? Natascha Wuillemin, Dolores Dina, Klara K. Eriksson, Daniel Yerly O3 Specific binding characteristics of HLA alleles associated with nevirapine hypersensitivity Rebecca Pavlos, Elizabeth Mckinnin, David Ostrov, Bjoern Peters, Soren Buus, David Koelle, Abha Chopra, Craig Rive, Alec Redwood, Susana Restrepo, Austin Bracey, Jing Yuan, Silvana Gaudieri, Mary Carrington, David Haas, Simon Mallal, Elizabeth Phillips O4 Do we need to measure total ige for the interpretation of analytical results of ImmunoCAP dnd 3gAllergy specific IgE? Douwe De Boer, Paul Menheere, Chris Nieuwhof, Judith Bons O5 Neutrophil activation in systemic anaphylaxis: results from the multicentric NASA study Friederike Jonsson, Luc De Chaisemartin, Vanessa Granger, Caitlin Gillis, Aurelie Gouel, Catherine Neukirch, Fadia Dib, Pascale Roland Nicaise, Dan Longrois, Florence Tubach, Sylvie Martin, Pierre Bruhns, NASA Study Group O6 Purpuric drug eruptions due to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) for non-small-cell lung cancer (NSCLC): a clinic-pathological study of 32 cases Kai-Lung Chen, Shu-Ling Liao, Yi-Shuan Sheen, Yung-Tsu Cho, Che-Wen Yang, Jau-Yu Liau, Chia-Yu Chu Poster presentations: Poster Walk 1—Anaphylaxis (P01–P09) P1 Anaphylactic reactions during anaesthesia and the perioperative period Rita Aguiar, Anabela Lopes, NatĂĄlia Fernandes, Leonor Viegas, M. A. Pereira-Barbosa P2 Anaphylaxis to chlorhexidine: is there a cross-reactivity to alexidine? Antonia BĂŒnter, Nisha Gupta, Tatjana Pecaric Petkovic, Nicole Wirth, Werner J. Pichler, Oliver Hausmann P3 Cefotaxime-induced severe anaphylaxis in a neonate Mehtap Yazicioglu, Pinar G. Ozdemir, Gokce Ciplak, Ozkan Kaya P4 Clinical features and diagnosis of anaphylaxis resulting from exposure to chlorhexidine Peter John Cooke P5 Drug-induced anaphylaxis: five-year single-center survey InĂȘs Mota, Ângela Gaspar, Filipe Benito-Garcia, Marta Chambel, MĂĄrio Morais-Almeida P6 Intraoperative severe anaphylactic reaction due to patent blue v dye Luis Marques, Eva Alcoceba, Silvia Lara P7 Kounis syndrome in the setting of anaphylaxis to diclofenac Leonor Carneiro-LeĂŁo, Carmen Botelho, Eunice Dias-Castro, Josefina Cernadas P8 Perioperative anaphylaxis audit: Royal Melbourne Hospital Katherine Nicholls, William Lay, Olivia Smith, Christine Collins, Gary Unglik, Kymble Spriggs, Priscilla Auyeung, Jeremy McComish, Jo A. Douglass P9 Recurrent peri-operative anaphylaxis: a perfect storm Jonny G. Peter, Paul Potter Poster Walk 2: DH regions and patient groups (P10–P19) P10 A rare presentation of amoxicillin allergy in a young child FabrĂ­cia Carolino, Eunice Dias De Castro, Josefina R. Cernadas P11 Adverse drug reactions in children: antibiotics or virus? Ana Sofia Moreira, Carmo Abreu, Eva Gomes P12 Allergic reactions in invasive medical procedures BĂĄrbara Kong Cardoso, Elza Tomaz, Sara Correia, Filipe InĂĄcio P13 Antibiotic allergy in children: room for improvement Annabelle Arnold, Natasha Bear, Kristina Rueter, Grace Gong, Michael O’Sullivan, Saravanan Muthusamy, Valerie Noble, Michaela Lucas P14 Drug hypersensitivity reactions in children and results of diagnostic evaluation Neringa Buterleviciute, Odilija Rudzeviciene P15 Nonimmediate cutaneous drug reactions in children: are skin tests required? Ana Sofia Moreira, Carmo Abreu, Eva Gomes P16 Pediatric patients with a history of penicillin allergy and a positive penicillin skin test may not be at an increased risk for multiple drug allergies Sara May, Thanai Pongdee, Miguel Park P17 Proved hypersensitivity to drugs according data of Vilnius University Hospital Santariskiu Klinikos Linas Griguola, Arturas Vinikovas, Simona KaĆĄinskaite, Violeta Kvedariene P18 Self-reported prevalence of drug hypersensitivity reactions among students in Celal Bayar University, Turkey Ayse Aktas, Suheyla Rahman, Huseyin Elbi, Beyhan Cengiz Ozyurt P19 Severe drug hypersensitivity reactions in pediatric age Ozlem Cavkaytar, Betul Karaatmaca, Pinar Gur Cetinkaya, Saliha Esenboga, Umit M. Sahiner, Bulent E. Sekerel, Ozge Soyer Poster Walk 3: Desensitisation (P20–P28) P20 A protocol for desensitisation to valaciclovir Celia Zubrinich, Bianca Tong, Mittal Patel, Michelle Giles, Robyn O’Hehir, Robert Puy P21 A rare case of desensitization to modafinil Josefina Cernadas, LuĂ­s Amaral, FabrĂ­cia Carolino P22 A sixteen-day desensitization protocol in delayed type hypersensitivity reactions to oral drugs Semra Demir, Asli Gelincik, Muge Olgac, Raif Caskun, Derya Unal, Bahauddin Colakoglu, Suna Buyukozturk P23 Desensitization to intravenous etoposide using a 12 and a 13-step protocol. Two cases report Olga Vega Matute, Amalia Bernad, Gabriel Gastaminza, Roselle Madamba, Carlos Lacasa, M. J. Goikoetxea, Carmen D’Amelio, Jose RifĂłn, Nicolas MartĂ­nez, Marta Ferrer P24 Drug desensitisation in oncology: the experience of an immunoallergology department for 5 years Carmelita Ribeiro, EmĂ­lia Faria, Cristina Frutuoso, Anabela Barros, RosĂĄrio Lebre, Alice Pego, Ana Todo Bom P25 Filgrastim anaphylaxis: a successful desensitization protocol Luis Amaral, Josefina Cernadas P26 Galsulfase hypersensitivity and desensitization of a mucopolysaccharidosis VI patient Luis Felipe Ensina, Carolina Aranda, Ines Camelo Nunes, Ana Maria Martins, Dirceu SolĂ© P27 Rapid drug desensitization with biologicals: one-center experience with four biologicals Sevim Bavbek, Resat Kendirlinan, Pamir Çerçi, Seda Tutluer, Sadan Soyyigit, Zeynep Çelebi Sözener, ÖmĂŒr Aydin, Reyhan GĂŒmĂŒsburun P28 Successful desensitization to a high dose of methotrexate in a delayed type hypersensitivity reaction Josefina Cernadas, Leonor Carneiro-LeĂŁo, FabrĂ­cia Carolino, Marta Almeida Poster Walk 4: SJS (P29–P38) P29 Assessment of impact of infection on drug-induced severe cutaneous adverse reactions and rhabdomyolysis using the Japanese adverse drug event report database Kimie Sai, Takuya Imatoh, Ryosuke Nakamura, Chisato Fukazawa, Yasushi Hinomura, Yoshiro Saito P30 Characterization of erythema multiforme and severe cutaneous adverse reactions hospitalizations Bernardo Sousa-Pinto, ClĂĄudia Correia, LĂ­dia Gomes, Sara Gil-Mata, LuĂ­s AraĂșjo, LuĂ­s Delgado P31 Effects of infection on incidence/severity of SJS/TEN and myopathy in Japanese cases analyzed by voluntary case reports Ryosuke Nakamura, Kimie Sai, Takuya Imatoh, Yoshimi Okamoto-Uchida, Koji Kajinami, Kayoko Matsunaga, Michiko Aihara, Yoshiro Saito P32 Efficacy of tumor necrosis factor—a antagonists in Stevens–Johnson syndrome and toxic epidermal necrolysis: a randomized controlled trial and immunosuppressive effects evaluation Chuang-Wei Wang, Shih-Chi Su, Shuen-Iu Hung, Hsin-Chun Ho, Chih-Hsun Yang, Wen-Hung Chung P33 Evolution of drug causality in Stevens–Johnson syndrome and toxic epidermal necrolysis in Europe: analysis of 10 years RegiSCAR-Study Maren Paulmann, Ariane Dunant, Maja Mockenhaupt, Peggy Sekula, Martin Schumacher, Sylvia Kardaun, Luigi Naldi, Teresa BellĂłn, Daniel Creamer, Cynthia Haddad, Bruno Sassolas, BĂ©nĂ©dicte Lebrun-Vignes, Laurence Valeyrie-Allanore, Jean-Claude Roujeau P34 Long-term sequelae in patients with Stevens–Johnson syndrome and toxic epidermal necrolysis: a 5-year analysis Maren Paulmann, Carmen Kremmler, Peggy Sekula, Laurence Valeyrie-Allanore, Luigi Naldi, Sylvia Kardaun, Maja Mockenhaupt P35 Major emotional complications and decreased health related quality of life among survivors of Stevens–Johnson syndrome and toxic epidermal necrolysis Roni P. Dodiuk-Gad, Cristina Olteanu, Anthony Feinstein, Rena Hashimoto, Raed Alhusayen, Sonia Whyte-Croasdaile, Yaron Finkelstein, Marjorie Burnett, Shachar Sade, Robert Cartotto, Marc Jeschke, Neil H. Shear P36 Retrospective analysis of Stevens–Johnson syndrome and toxic epidermal necrolysis in Japanese patients: treatment and outcome Naoko Takamura, Yumiko Yamane, Setsuko Matsukura, Kazuko Nakamura, Yuko Watanabe, Yukie Yamaguchi, Takeshi Kambara, Zenro Ikezawa, Michiko Aihara P37 Severe physical complications among survivors of Stevens–Johnson syndrome and toxic epidermal necrolysis Roni P. Dodiuk-Gad, Cristina Olteanu, Rena Hashimoto, Hall Chew, Raed Alhusayen, Sonia Whyte-Croasdaile, Yaron Finkelstein, Marjorie Burnett, Shachar Sade, Robert Cartotto, Marc Jeschke, Neil H. Shear P38 Stevens–Johnson syndrome/toxic epidermal necrolysis combined with haemophagocytic lymphohistiocytosis: a case report Brittany Knezevic, Una Nic Ionmhain, Allison Barraclough, Michaela Lucas, Matthew Anstey Poster Walk 5: Other organs/unexpected immune reactions (P39–P47) P39 A case report of patient with anti-tuberculosis drug-related severe liver failure Toru Usui, Xiaoli Meng, John Farrell, Paul Whitaker, John Watson, Neil French, Kevin Park, Dean Naisbitt P40 Acute interstitial nephritis induced by ibuprofen Ana Castro Neves, Susana Cadinha, Ana Moreira, J. P. Moreira Da Silva P41 Cetuximab induced acneiform rash—two case reports Daniela Ledic Drvar, Sandra Jerkovic Gulin, Suzana Ljubojevic Hadzavdic, Romana Ceovic P42 Enteropathy associated with losartan Ana Montoro De Francisco, TalĂ­a De Vicente JimĂ©nez, Amelia GarcĂ­a Luque, Natalia Rosado David, JosĂ© MÂȘ Mateos GalvĂĄn P43 Granuloma annulare after therapy with canakinumab Razvigor Darlenski P44 Hypersensitivity eosinophilic myocarditis or acute coronary syndrome? Case report Dario Gulin, Jozica Sikic, Jasna Cerkez Habek, Sandra Jerkovic Gulin, Edvard Galic P45 Piperacillin-induced immune haemolytic anaemia: a severe and frequent complication of antibiotic treatment in patients with cystic fibrosis Philip Specht, Doris Staab, Beate Mayer, Jobst Roehmel P46 Progesterone triggered pemphigus foliaceus: case report Sandra Jerkovic Gulin, Caius Solovan, Anca Chiriac P47 Ramipril: triggered generalized pustular psoriasis Paola Djurinec, Kresimir Kostovic, Mirna Bradamante, Sandra Jerkovic Gulin, Romana Ceovic Poster Walk 6: NSAIDs (P48–P56) P48 Aspirin desensitization in cardiovascular disease—Portuguese experience Jose Pedro Almeida, Joana Caiado, Elisa Pedro, Pedro Canas Da Silva, Manuel Pereira Barbosa P49 Asthma and/or rhinitis to NSAIDs with good tolerance to ASA Gador Bogas, Natalia Blanca-LĂłpez, Diana PĂ©rez-Alzate, Inmaculada Doña, JosĂ© Augusto AgĂșndez, Elena GarcĂ­a-MartĂ­n, JosĂ© Antonio Cornejo-GarcĂ­a, Cristobalina Mayorga, MarĂ­a JosĂ© Torres, Gabriela Canto, Miguel Blanca P50 Clinical characteristics of 196 patients with non-steroidal anti-inflammatory drug (NSAIDs) hypersensitivity SengĂŒl Aksakal, AytĂŒl Zerrin Sin, Zeynep Peker Koç, Fatma DĂŒsĂŒnĂŒr GĂŒnsen, ÖmĂŒr Ardeniz, Emine Nihal Mete Gökmen, Okan GĂŒlbahar, Ali Kokuludag P51 Development of immediate hypersensitivity to several NSAIDs maintaining good tolerance to ASA Natalia PĂ©rez-SĂĄnchez, Natalia Blanca-LĂłpez, Diana PĂ©rez-Alzate, Gador Bogas, Inmaculada Doña, MarĂ­a Salas, MarĂ­a JosĂ© Torres, Miguel Blanca, Gabriela Canto P52 Diagnosis of hypersensitivity reactions to paracetamol in a large series of cases Inmaculada Doña, Maria Salas, Francisca Gomez, Natalia Blanca-Lopez, Diana Perez-Alzate, Gador Bogas, Esther Barrionuevo, Maria Jose Torres, Inmaculada Andreu, Miguel Ángel Miranda, Gabriela Canto, Miguel Blanca P53 Hypersensitivity to paracetamol according to the new classification of hypersensitivity to NSAIDs Gabija DidĆŸiokaite, Olesia Gaidej, Simona KaĆĄinskaite, Violeta Kvedariene P54 Ibuprofen and other aryl propionic derivates can induce immediate selective hypersensitivity responses Diana Perez-Alzate, Natalia Blanca-LĂłpez, Maria Isabel Garcimartin, Inmaculada Doña, Maria Luisa Somoza, Cristobalina Mayorga, Maria Jose Torres, Gador Bojas, Jose Antonio Cornejo-Garcia, Maria Gabriela Canto, Miguel Blanca P55 Subjects developing immediate responses to several NSAIDs can be selective with good tolerance to ASA Natalia Blanca-Lopez, Diana PĂ©rez-Alzate, Francisco Javier Ruano Perez, Inmaculada Doña, Maria Luisa Somoza, Inmaculada Andreu, Miguel Angel Miranda, Cristobalina Mayorga, Maria Jose Torres, Jose Antonio Cornejo-Garcia, Miguel Blanca, Maria Gabriela Canto P56 Utility of low-dose oral aspirin challenges for diagnosis of aspirin exacerbated respiratory disease Elina Jerschow, Teresa Pelletier, Zhen Ren, Golda Hudes, Marek Sanak, Esperanza Morales, Victor Schuster, Simon D. Spivack, David Rosenstreich Poster Walk 7: NSAID 2 (P57–P65) P57 Alternate regulation of cyclooxygenase-2 (COX-2) MRNA expression may predispose patients to aspirin-induced exacerbations Renato Erzen, Mira Silar, Nissera Bajrovic, Matija Rijavec, Mihaela Zidarn, Peter Korosec P58 Anaphylaxis to diclofenac: what about the underlying mechanism? Leonor Carneiro-LeĂŁo, FabrĂ­cia Carolino, LuĂ­s Amaral, Carmen Botelho, Eunice Dias-Castro, Josefina Cernadas P59 COX-2 inhibitors: are they always a safe alternative in hypersensitivity to nonsteroidal anti-inflammatory drugs? Luis Amaral, Fabricia Carolino, Eunice Castro, Josefina Cernadas P60 Management of patients with history of NSAIDs reactions prior to coronary angioplasty Mona Al-Ahmad, Tito Rodriguez P61 Oral drug challenge with non-steroidal anti-inflammatory drug under spirometric control: clinical series of 110 patients JoĂŁo Pedro Azevedo, EmĂ­lia Faria, Beatriz Tavares, Frederico Regateiro, Ana Todo-Bom P62 Prevalence and incidence of analgesic hypersensitivity reactions in Colombia Pablo AndrĂ©s Miranda, Bautista De La Cruz Hoyos P63 Recent endoscopic sinus surgery lessens reactions during aspirin challenge in patients with aspirin exacerbated respiratory disease Teresa Pelletier, Waleed Abuzeid, Nadeem Akbar, Marc Gibber, Marvin Fried, Weiguo Han, Taha Keskin, Robert Tamayev, Golda Hudes, Simon D. Spivack, David Rosenstreich, Elina Jerschow P64 Safe use of imidazole salycilate in a case of multiple NSAIDs induced urticaria-angioedema Elisa Boni, Marina Russello, Marina Mauro P65 Selective hypersensitivity reactions to ibuprofen—seven years experience Marta Ferreira Neto Poster Walk 8: Epidemiological methods (P66–P72) P66 Allopurinol hypersensitivity: a 7-year review Lise Brosseron, Daniela Malheiro, Susana Cadinha, PatrĂ­cia Barreira, J. P. Moreira Da Silva P67 Antibiotic allergy labelling is associated with increased hospital readmission rates in Australia Brittany Knezevic, Dustin Sprigg, Michelle Trevenen, Jason Seet, Jason Trubiano, William Smith, Yogesh Jeelall, Sandra Vale, Richard Loh, Andrew Mclean-Tooke, Michaela Lucas P68 Experts’ opinions on severe cutaneous adverse drug reactions-report of a survey from the 9th international congress on cutaneous adverse drug reactions 2015 Roni P. Dodiuk-Gad, Cristina Olteanu, Wen-Hung Chung, Neil H. Shear P69 HLA-A*31-positive AGEP with carbamazepine use and other severe cutaneous adverse drug reactions (SCARs) detected by electronic medical records screening Sabine MĂŒller, Ursula Amstutz, Lukas Jörg, Nikhil Yawalkar, Stephan KrĂ€henbĂŒhl P70 Patients with suspected drug allergy: a specific psychological profile? Eunice Dias-Castro, Ana Leblanc, Laura Ribeiro, Josefina R. Cernadas P71 Use of an electronic device and a computerized mathematic algorithm to detect the allergic drug reactions through the analysis of heart rate variability Arantza Vega, Raquel Gutierrez Rivas, Ana Alonso, Juan Maria Beitia, BelĂ©n Mateo, Remedios CĂĄrdenas, Juan Jesus Garcia-Dominguez P72 Variation in ERAP influences risk for HLA-B*57:01 positive abacavir hypersensitivity Rebecca Pavlos, Kaija Strautins, Ian James, Simon Mallal, Alec Redwood, Elizabeth Phillips Poster Walk 9: DRESS/AGEP (P73–P81) P73 A clinical case of DRESS syndrome in a child after administration of amoxicillin-clavulanic acid Rita Aguiar, Anabela Lopes, Ana Neves, Maria Do CĂ©u Machado, M. A. Pereira-Barbosa P74 Acute generalized exanthematous pustulosis (AGEP) induced by mesalazine, reliable and oftenly used drug to treat inflammatory bowel disease Ceyda Tunakan Dalgiç, Emine Nihal Mete Gökmen, Fatma DĂŒsĂŒnĂŒr GĂŒnsen, Gökten Bulut, Fatma ÖmĂŒr Ardeniz, Okan GĂŒlbahar, Ali Kokuludag, AytĂŒl Zerrin Sin P75 Changes of blood plasmacytoid dendritic cells, myeloid dendritic cells, and basophils during the acute stage of drug reaction with eosinophilia and systemic symptoms (DRESS) and other drug eruptions Shao-Hsuan Hsu, Yung-Tsu Cho, Che-Wen Yang, Kai-Lung Chen, Chia-Yu Chu P76 Characterization of isoniazid/rifampicin-specific t-cell responses in patients with DRESS syndrome Young-Min Ye, Gyu-Young Hur, Hae-Sim Park, Seung-Hyun Kim P77 DRESS syndrome secondary to sulfasalazine with delayed TEN: a case presentation Syed Ali, Michaela Lucas, Peter N. Hollingsworth, Andrew P. C. Mclean-Tooke P78 Drug rash with eosinophilia and systemic symptoms (DRESS) features according to the culprit drug Zohra Chadly, Nadia Ben Fredj, Karim Aouam, Haifa Ben Romdhane, Naceur A. Boughattas, Amel Chaabane P79 Drug reaction with eosinophilia and systemic symptoms induced by allopurinol: not always easy to diagnose Marina Lluncor Salazar, Beatriz Pola, Ana Fiandor, Teresa BellĂłn, Elena RamĂ­rez, Javier DomĂ­nguez Ortega, Santiago Quirce, Rosario Cabañas P80 Drug reaction with eosinophilia and systemic symptoms syndrome induced by two drugs simultaneously: a case report Krasimira Baynova, Marina Labella, Manuel Prados P81 The drug reaction with eosinophilia and systemic symptoms (DRESS) induced by the second-line antituberculosis drugs and Epstein–Barr virus infection Agne Ramonaite, Ieva Bajoriuniene, Brigita Sitkauskiene, Raimundas Sakalauskas Poster Walk 10: Miscellaneous drug hypersensitivity (P82–P91) P82 A case of cycloserine-induced lichenoid drug eruption confirmed with a lymphocatye transformation test Jae-Woo Kwon, Shinyoung Park P83 Allergic reaction to topical eye drops: 5 years’ retrospective study in a drug allergy unit Diana Silva, Leonor Carneiro LeĂŁo, Fabricia Carolino, Eunice Castro, Josefina Cernadas P84 Allergy to heparins Diana Perez-Alzate, Natalia Blanca-LĂłpez, Maria Luisa Somoza Alvarez, Maria Garcimartin, Maria Vazquez De La Torre, Francisco Javier Ruano PĂ©rez, Elisa Haroun, Gabriela Canto Diez P85 Allopurinol-induced adverse drug reactions Katinka Ónodi-Nagy, Ágnes KinyĂł, Lajos KemĂ©ny, Zsuzsanna Bata-Csörgo P86 Analysis of a population with immediate hypersensitivity to corticosteroids: an 11 year review Joana Sofia Pita, EmĂ­lia Faria, Rosa Anita Fernandes, Ana Moura, Nuno Sousa, Carmelita Ribeiro, Carlos Loureiro, Ana Todo Bom P87 Anaphylaxis against mivacurium in a 12-months old boy at first-time exposure Wolfgang PfĂŒtzner P88 Antihistamine-exacerbated chronic spontaneous urticaria: a paradox? Nadine Marrouche, Clive Grattan P89 Anti-osteoporotic agents-induced cutaneous adverse drug reactions in Asians Yu-En Chen, Chun-Bing Chen, Wen-Hung Chung, Yu-
    corecore